Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 7/4/2008 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong C.L. Kaul?

C.L. Kaul

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Director

National Institute of Pharmaceutical Education and Research


Director

Asian Technology Information Program


Executive Editor

Ayurveda Rasayani


Director , National Institute of Pharmaceutical Education & Research


Web References(13 Total References)


www.clinicpune.org

· Dr. C.L. Kaul.Advisor, CRCDM Bioinformatics Centre, University of Pune, Former Director of NIPER.


www.pharmabiz.com [cached]

Dr Chaman Lal Kaul, director, National Institute of Pharmaceutical Education and Research (NIPER)Dr Chaman Lal Kaul, the first and serving director of NIPER


www.atip.org

Dr. C. L. Kaul, Director of the Institute, is working on new drug development, diabetic research, and tropical disorders.
1) Dr. C. L. Kaul, Director, Niper Tel: 91-40-2214690, 91-40-2214697 ext. 2001, 2002 E-mail: This e-mail address is being protected from spambots.


www.rasayu.com [cached]

Dr C L Kaul


www.blonnet.com [cached]

OUTLINING the current threats and opportunities of the pharmaceutical industry in a globally competitive environment, Dr C.L. Kaul, Director, National Institute of Pharmaceutical Education & Research, Chandigarh, has cautioned that with the advent of the patent regime by 2005, the pharma sector would no longer have the advantage of reverse engineering, which has been its strength and core business area. He said the fast changing regulatory and intellectual property scenario would demand realignment of business activities of pharmaceutical companies.He felt "our companies' inherent manufacturing strengths can be leveraged to acquire a substantial share of $10-15 billion of global manufacturing outsourcing market."Good manufacturing practices would increasingly come to reflect the policies of the organisations. Addressing a workshop on `Good manufacturing practices (GMP) of modern and herbal drugs: A tool for competitive advantage', organised by the Indian Chemical Manufacturers' Association (ICMA) here, Dr Kaul said in the changed economic scenario, "we need to strengthen our drive towards total quality management." He said this would involve extension and awareness of quality into various operations of the organisation to foster an enduring quality culture. Describing the above as an arduous task involving various elements, he said a key factor was the involvement of the top management, who should believe that quality would lead to improved profits in the long run.Pointing out that there had been a paradigm shift in the last two decades in all aspects of production and marketing of pharmaceutical products, he said outsourcing would emerge as a major challenge for the pharma sector in the new globally competitive environment.He predicted that contract manufacturing opportunities for drug companies would emerge in a big way, as the number of global pharma majors may shrink to just 10 by 2010. Dr Kaul said the key areas of GMP of companies which now needed attention were product design, stability testing (which was difficult and expensive, but could not be overlooked), manufacturing process, packaging controls, vendor relation and audit quality, personnel and training and complaints. He said the same standards of manufacturing as applicable to modern medicines should also apply to herbal products, irrespective of the fact whether they were new entities, well established products or traditionally used products.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory